MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Fermé

3.91 6.25

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.73

Max

3.95

Chiffres clés

By Trading Economics

Revenu

44M

-26M

Ventes

-5.8M

42M

Marge bénéficiaire

-61.388

Employés

550

EBITDA

44M

-22M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+15.18% upside

Dividendes

By Dow Jones

Prochains Résultats

17 mars 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

367M

1.4B

Ouverture précédente

-2.34

Clôture précédente

3.91

Score Technique

By Trading Central

Confiance

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

16 janv. 2026, 23:29 UTC

Actions en Tendance

Stocks to Watch: Atossa Therapeutics, Union Pacific

16 janv. 2026, 22:48 UTC

Acquisitions, Fusions, Rachats

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 janv. 2026, 22:43 UTC

Acquisitions, Fusions, Rachats

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 janv. 2026, 22:22 UTC

Acquisitions, Fusions, Rachats

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 janv. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

16 janv. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Auto & Transport Roundup: Market Talk

16 janv. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 janv. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

16 janv. 2026, 21:48 UTC

Market Talk
Acquisitions, Fusions, Rachats

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 janv. 2026, 21:41 UTC

Market Talk
Acquisitions, Fusions, Rachats

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 janv. 2026, 21:38 UTC

Acquisitions, Fusions, Rachats

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 janv. 2026, 20:44 UTC

Résultats

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 janv. 2026, 20:42 UTC

Market Talk

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 janv. 2026, 20:28 UTC

Market Talk

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 janv. 2026, 19:12 UTC

Market Talk
Acquisitions, Fusions, Rachats

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 janv. 2026, 18:53 UTC

Market Talk

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 janv. 2026, 18:41 UTC

Market Talk

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 janv. 2026, 18:31 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 janv. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

16 janv. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 janv. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

16 janv. 2026, 17:03 UTC

Market Talk

Global Equities Roundup: Market Talk

16 janv. 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16 janv. 2026, 16:32 UTC

Market Talk
Acquisitions, Fusions, Rachats

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16 janv. 2026, 16:20 UTC

Market Talk

Global Equities Roundup: Market Talk

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

15.18% hausse

Prévisions sur 12 Mois

Moyen 4.25 USD  15.18%

Haut 4.5 USD

Bas 4 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

3

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

2.02 / 2.115Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat